Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 0.46 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10818203 | 0.85 | SLC5A1 (0.40) | P2RX7SLC5A1TSHR | |
| SCHEMBL11201289 | 0.83 | P2RX7 (0.45) | P2RX7SLC5A1L3MBTL1 | |
| SCHEMBL11293011 | 0.82 | MEN1 (0.41) | P2RX7SLC5A1KMT2ATDP1ACE | |
| SCHEMBL14827922 | 0.81 | P2RX7 (0.43) | P2RX7SLC5A1L3MBTL1KMT2ATSHR | |
| SCHEMBL15129469 | 0.79 | ABL1 (0.48) | KMT2ATDP1TSHR | |
| SCHEMBL1637706 | 0.76 | P2RX7 (0.41) | P2RX7SLC5A1 | |
| SCHEMBL4293137 | 0.74 | EHMT2 (0.45) | KMT2AACETSHR | |
| SCHEMBL10476562 | 0.74 | — | — | |
| SCHEMBL288354 | 0.74 | P2RX7 (0.45) | P2RX7SLC5A1ACETSHR | |
| SCHEMBL14750046 | 0.74 | P2RX7 (0.45) | P2RX7SLC5A1ACETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4631573-A2 | TEAD INHIBITORS | Orion Corporation (FI) | 2025-10-15 | — | — | EP | disclosed |
| EP-4323338-B1 | TEAD INHIBITORS | ORION CORP (FI) | 2025-10-08 | — | — | EP | disclosed |
| US-7932282-B2 | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2011-04-26 | — | — | US | disclosed |
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | GLAXO GROUP LIMITED (GB) | 2010-03-25 | — | — | US | disclosed |
| CN-101679291-A | Imidazolidine carboxamide derivatives as P2X7 modulators | GLAXO GROUP LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2142512-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119825-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075968-A1 | Imidazolidine Carboxamide Derivatives as P2X7 Modulators | P2RX3, P2RX7, P2RX5 | P2RX7 2/4885SLC5A1 314/4885L3MBTL1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.